From Small Fragments to Big Drugs: Fragment-based Drug Discovery
Dan Erlanson, Ph.D | Co-founder and VP of Chemistry | Carmot Therapeutics
From Fragments to Drugs: Playing Quick Molecular Scrabble with Protein Crystallography
Debanu Das, Ph.D | Co-founder and CEO | Accelero Biostructures
Role of DMPK in Drug Discovery and Development
JP Shaw, Ph.D | Independent Pre-Clinical DMPK Consultant
Paving the Road to the Clinic: Advancing Oncology Drug Development with Translational In Vitro and In Vivo Models
Tommy Broudy, Ph.D | CEO | Molecular Response
BioDuro Solution Engine: Enabled Formulations Bridging Discovery and Development
Blair West, Ph.D | Chief Science Officer, Global CMC Solutions | BioDuro
Rapid Development and Scale-up of Solubilized Dosage Forms
Ruchit Trivedi, Ph.D | Associate Director, Formulation | BioDuro
Interested in a presentation?
Request a copy using the form below.
How can we accelerate successful drug discovery and development?
The success of clinical candidate development depends on several factors, important among them are generation of novel, therapeutically-relevant chemical structures, early and rapid assessment of possible efficacy of candidate structures in pre-clinical therapeutic models and rapid elimination of candidates that will ultimately prove unsuccessful. Innovative processes and techniques that facilitate optimal candidate selection is a crucial step in accelerating drug discovery and development timelines.
DATE AND TIME:
Thursday, March 22, 2018
11:30 AM – 6:30 PM PDT
Hilton Garden Inn San Francisco Airport North
670 Gateway Blvd
South San Francisco, CA 94080
11:30 PM- 12:30 PM
12:30 PM- 5:15 PM
Networking Happy Hour
5:15 PM- 6:30 PM